REZOLYuTsIYa PO ITOGAM EKSPERTNOGO SOVETA PO PROBLEMAM DIFFERENTsIROVANNOGO PODKhODA K TERAPII SNMP Novorossiysk, 8 iyunya 2019 g
- Authors: - -
- Issue: No 4 (2019)
- Pages: 6-8
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312216
- ID: 312216
Cite item
Open Access
Access granted
Abstract
Full Text
References
- Пушкарь Д.Ю., Раснер П.И. Харчилава Р.Р. Симптомы нижних мочевых путей и доброкачественная гиперплазия предстательной железы. Урология, 2016;2(Приложение ):4-19.
- Abrams P., et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21: 167.
- Martin S.A., Haren M.T., Marshall V.R., Lange K., Wittert G.A. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol. 2011;29(2):179-184. doi : 10,1007 / s00345-010-0605-8.
- Irwin D. et al. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. European Urology. 2007;50(6):1306-1315.
- Guess H.A. Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clin. North. Am. 1995;22:247-261.
- EAU 2019 Доступно на http://uroweb.org/guideline/treatment-of-non-neurogenicmale-luts/
- Kaplan SA. New data on tolterodine: do recent findings dispel questions about treating overactive bladder in men? European Urology 2007;6(Suppl.):10-16.
- Antunes A.A. Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate? J Urol. 2015 ; 193(6) :2028-2032. doi: 10.1016/j.juro.2014.12.095. Epub 2015 Jan 9.
- Milsom I.P. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU International. 2001;87:760-766.
- Michel M.C., et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332.
- Drake M.J. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33:622.
- Benner J.S. et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276-1282.
- Wagg A. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. 2012 BJU INTERNATIONAL. Doi:10.1111/ j.1464-410X.2012.11023.x
- Takasu T. et al. Effect of (R)-2-(2-Aminothiazol-4-yl)-4_-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective _3-Adrenoceptor Agonist, on Bladder Function. J Pharmacol Exp Ther. 2007;321(2):642-647.
- Nitti V.W. et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. J Clin Pract. doi: 10.1111/ijcp.12194.
- Kakizaki H. et al. Efficacy and safety of add-on mirabegron vs. placebo to tamsulosin in men with overactive bladder symptoms (match study). The Journal of Urology. 2018;199(4S, Suppl.).
- Ichihara K. et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921-926. doi: 10.1016/j.juro.2014.09.091. Epub 2014 Sep 22.
- Tubaro A. et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol 2017;9(6):137-154. doi: 10.1177/1756287217702797.
- Haab F. et al. Long-TermOpen-Label Solifenacin Treatment Associated with Persistence with Therapy in Patients with Overactive Bladder Syndrome. Eur Urol. 2005; 47: 376-384.
- Drake M. et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). European Urology. 2016;70:136-145.
- Abrams P et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577-588. doi: 10.1016/j.eururo.2014.02.012.
- Gratzke C. at al. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018; 74(4):501-509. Doi: 10.1016/j. eururo.2018.05.005. Epub 2018 Jun 1.
Supplementary files
